{"transactions":[{"id":4628863,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-10-02T22:15:10.000Z","date":"2026-09-30","kind":"exercise","planned":false,"acquired":false,"shares":4384,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":35115,"derivative":{"underlying":"Common Stock","underlying_shares":4384},"source":{"system":"sec-edgar","filing":"0001437749-26-031927","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774926031927/rdgdoc.xml","form_type":"4"}},{"id":4628862,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-10-02T22:15:10.000Z","date":"2026-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":1944,"price":79.67,"value":154878.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":58054,"source":{"system":"sec-edgar","filing":"0001437749-26-031927","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774926031927/rdgdoc.xml","form_type":"4"}},{"id":4628861,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-10-02T22:15:10.000Z","date":"2026-09-30","kind":"exercise","planned":false,"acquired":true,"shares":4384,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":59998,"source":{"system":"sec-edgar","filing":"0001437749-26-031927","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774926031927/rdgdoc.xml","form_type":"4"}},{"id":718308,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-07-02T23:37:33.000Z","date":"2026-06-30","kind":"exercise","planned":false,"acquired":false,"shares":5254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":39499,"derivative":{"underlying":"Common Stock","underlying_shares":5254},"source":{"system":"sec-edgar","filing":"0001437749-26-022628","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774926022628/rdgdoc.xml","form_type":"4"}},{"id":718307,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-07-02T23:37:33.000Z","date":"2026-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":2309,"price":92.59,"value":213790.31,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":55614,"source":{"system":"sec-edgar","filing":"0001437749-26-022628","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774926022628/rdgdoc.xml","form_type":"4"}},{"id":718306,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-07-02T23:37:33.000Z","date":"2026-06-30","kind":"exercise","planned":false,"acquired":true,"shares":5254,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":57923,"source":{"system":"sec-edgar","filing":"0001437749-26-022628","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774926022628/rdgdoc.xml","form_type":"4"}},{"id":819836,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-04-02T19:03:03.000Z","date":"2026-03-31","kind":"exercise","planned":false,"acquired":false,"shares":3514,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":44753,"derivative":{"underlying":"Common Stock","underlying_shares":3514},"source":{"system":"sec-edgar","filing":"0001437749-26-011078","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774926011078/rdgdoc.xml","form_type":"4"}},{"id":819835,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-04-02T19:03:03.000Z","date":"2026-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":1571,"price":54.79,"value":86075.09,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":52669,"source":{"system":"sec-edgar","filing":"0001437749-26-011078","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774926011078/rdgdoc.xml","form_type":"4"}},{"id":819834,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-04-02T19:03:03.000Z","date":"2026-03-31","kind":"exercise","planned":false,"acquired":true,"shares":3514,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":54240,"source":{"system":"sec-edgar","filing":"0001437749-26-011078","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774926011078/rdgdoc.xml","form_type":"4"}},{"id":951883,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-05T20:45:58.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":4326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":48267,"derivative":{"underlying":"Common Stock","underlying_shares":4326},"source":{"system":"sec-edgar","filing":"0001437749-26-000305","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774926000305/rdgdoc.xml","form_type":"4"}},{"id":951882,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-01-05T20:45:58.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":1889,"price":65.3,"value":123351.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":50726,"source":{"system":"sec-edgar","filing":"0001437749-26-000305","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774926000305/rdgdoc.xml","form_type":"4"}},{"id":951881,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-01-05T20:45:58.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":4326,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":52615,"source":{"system":"sec-edgar","filing":"0001437749-26-000305","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774926000305/rdgdoc.xml","form_type":"4"}},{"id":977753,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2025-12-08T21:50:48.000Z","date":"2025-12-02","kind":"grant","planned":false,"acquired":true,"shares":13919,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2026, and 3/48ths per quarter thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2026, and 3/48ths per quarter thereafter."}],"balance_after":52593,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":13919},"source":{"system":"sec-edgar","filing":"0001437749-25-037171","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925037171/rdgdoc.xml","form_type":"4"}},{"id":977752,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2025-12-08T21:50:48.000Z","date":"2025-12-02","kind":"grant","planned":false,"acquired":true,"shares":8969,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 6/48ths on June 30, 2026, and 1/48th per month thereafter."}],"balance_after":8969,"derivative":{"exercise_price":75.94,"expiration_date":"2035-12-02","underlying":"Common Stock","underlying_shares":8969},"source":{"system":"sec-edgar","filing":"0001437749-25-037171","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925037171/rdgdoc.xml","form_type":"4"}},{"id":1027502,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2025-10-02T19:04:36.000Z","date":"2025-09-30","kind":"exercise","planned":false,"acquired":false,"shares":4327,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":38674,"derivative":{"underlying":"Common Stock","underlying_shares":4327},"source":{"system":"sec-edgar","filing":"0001437749-25-030285","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925030285/rdgdoc.xml","form_type":"4"}},{"id":1027501,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-10-02T19:04:36.000Z","date":"2025-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":1896,"price":81.67,"value":154846.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":48289,"source":{"system":"sec-edgar","filing":"0001437749-25-030285","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925030285/rdgdoc.xml","form_type":"4"}},{"id":1027500,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-10-02T19:04:36.000Z","date":"2025-09-30","kind":"exercise","planned":false,"acquired":true,"shares":4327,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":50185,"source":{"system":"sec-edgar","filing":"0001437749-25-030285","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925030285/rdgdoc.xml","form_type":"4"}},{"id":1095500,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2025-07-02T20:24:13.000Z","date":"2025-06-30","kind":"exercise","planned":false,"acquired":false,"shares":6863,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":43001,"derivative":{"underlying":"Common Stock","underlying_shares":6863},"source":{"system":"sec-edgar","filing":"0001437749-25-021993","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925021993/rdgdoc.xml","form_type":"4"}},{"id":1095499,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-07-02T20:24:13.000Z","date":"2025-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":2990,"price":35.78,"value":106982.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":45858,"source":{"system":"sec-edgar","filing":"0001437749-25-021993","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925021993/rdgdoc.xml","form_type":"4"}},{"id":1095498,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-07-02T20:24:13.000Z","date":"2025-06-30","kind":"exercise","planned":false,"acquired":true,"shares":6863,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":48848,"source":{"system":"sec-edgar","filing":"0001437749-25-021993","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925021993/rdgdoc.xml","form_type":"4"}},{"id":1183804,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2025-04-03T01:08:37.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":false,"shares":1791,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":49864,"derivative":{"underlying":"Common Stock","underlying_shares":1791},"source":{"system":"sec-edgar","filing":"0001437749-25-010810","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925010810/rdgdoc.xml","form_type":"4"}},{"id":1183803,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-04-03T01:08:37.000Z","date":"2025-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":744,"price":36.41,"value":27089.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":41985,"source":{"system":"sec-edgar","filing":"0001437749-25-010810","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925010810/rdgdoc.xml","form_type":"4"}},{"id":1183802,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-04-03T01:08:37.000Z","date":"2025-03-31","kind":"exercise","planned":false,"acquired":true,"shares":1791,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":42729,"source":{"system":"sec-edgar","filing":"0001437749-25-010810","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925010810/rdgdoc.xml","form_type":"4"}},{"id":1217663,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-08T02:09:50.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":40581,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter."}],"balance_after":51655,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":40581},"source":{"system":"sec-edgar","filing":"0001437749-25-006735","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925006735/rdgdoc.xml","form_type":"4"}},{"id":1217662,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2025-03-08T02:09:50.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":43445,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options Vests 6/48ths on June 30, 2025, and 1/48th per month thereafter."}],"balance_after":43445,"derivative":{"exercise_price":31.7,"expiration_date":"2035-03-04","underlying":"Common Stock","underlying_shares":43445},"source":{"system":"sec-edgar","filing":"0001437749-25-006735","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925006735/rdgdoc.xml","form_type":"4"}},{"id":1318799,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-02T23:15:33.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":false,"shares":1790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":11074,"derivative":{"underlying":"Common Stock","underlying_shares":1790},"source":{"system":"sec-edgar","filing":"0001437749-25-000097","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925000097/rdgdoc.xml","form_type":"4"}},{"id":1318798,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-01-02T23:15:33.000Z","date":"2024-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":721,"price":22,"value":15862.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":40938,"source":{"system":"sec-edgar","filing":"0001437749-25-000097","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925000097/rdgdoc.xml","form_type":"4"}},{"id":1318797,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-01-02T23:15:33.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":true,"shares":1790,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":41659,"source":{"system":"sec-edgar","filing":"0001437749-25-000097","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774925000097/rdgdoc.xml","form_type":"4"}},{"id":1394738,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2024-10-02T23:44:01.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":false,"shares":1791,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":12864,"derivative":{"underlying":"Common Stock","underlying_shares":1791},"source":{"system":"sec-edgar","filing":"0001437749-24-030535","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924030535/rdgdoc.xml","form_type":"4"}},{"id":1394737,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-10-02T23:44:01.000Z","date":"2024-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":535,"price":6.74,"value":3605.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":39869,"source":{"system":"sec-edgar","filing":"0001437749-24-030535","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924030535/rdgdoc.xml","form_type":"4"}},{"id":1394736,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-10-02T23:44:01.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":true,"shares":1791,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":40404,"source":{"system":"sec-edgar","filing":"0001437749-24-030535","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924030535/rdgdoc.xml","form_type":"4"}},{"id":1463362,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2024-07-02T22:12:26.000Z","date":"2024-06-30","kind":"exercise","planned":false,"acquired":false,"shares":8952,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":73271,"derivative":{"underlying":"Common Stock","underlying_shares":8952},"source":{"system":"sec-edgar","filing":"0001437749-24-022025","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924022025/rdgdoc.xml","form_type":"4"}},{"id":1463361,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-07-02T22:12:26.000Z","date":"2024-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":2019,"price":0.731,"value":1475.889,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":193065,"source":{"system":"sec-edgar","filing":"0001437749-24-022025","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924022025/rdgdoc.xml","form_type":"4"}},{"id":1463360,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-07-02T22:12:26.000Z","date":"2024-06-30","kind":"exercise","planned":false,"acquired":true,"shares":8952,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":195084,"source":{"system":"sec-edgar","filing":"0001437749-24-022025","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924022025/rdgdoc.xml","form_type":"4"}},{"id":1472214,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-06-21T21:16:51.000Z","date":"2024-06-20","kind":"purchase","planned":false,"acquired":true,"shares":20508,"price":0.7438,"value":15253.8504,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.73691 to $0.75860, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence."}],"balance_after":186132,"source":{"system":"sec-edgar","filing":"0001437749-24-021000","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924021000/rdgdoc.xml","form_type":"4"}},{"id":1472213,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-06-21T21:16:51.000Z","date":"2024-06-18","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":0.86,"value":10320.0,"ownership":{"direct":true},"balance_after":165624,"source":{"system":"sec-edgar","filing":"0001437749-24-021000","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924021000/rdgdoc.xml","form_type":"4"}},{"id":1477472,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-06-17T22:08:20.000Z","date":"2024-06-17","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":0.8999,"value":10798.8,"ownership":{"direct":true},"balance_after":153624,"source":{"system":"sec-edgar","filing":"0001437749-24-020547","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924020547/rdgdoc.xml","form_type":"4"}},{"id":1477471,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-06-17T22:08:20.000Z","date":"2024-06-14","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":0.9313,"value":11175.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9100 to $0.93994, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence."}],"balance_after":141624,"source":{"system":"sec-edgar","filing":"0001437749-24-020547","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924020547/rdgdoc.xml","form_type":"4"}},{"id":1477470,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-06-17T22:08:20.000Z","date":"2024-06-13","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":0.91,"value":10920.0,"ownership":{"direct":true},"balance_after":129624,"source":{"system":"sec-edgar","filing":"0001437749-24-020547","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924020547/rdgdoc.xml","form_type":"4"}},{"id":1490276,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-06-05T22:12:38.000Z","date":"2024-06-04","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":0.78,"value":9360.0,"ownership":{"direct":true},"balance_after":117624,"source":{"system":"sec-edgar","filing":"0001437749-24-019370","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924019370/rdgdoc.xml","form_type":"4"}},{"id":1490275,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-06-05T22:12:38.000Z","date":"2024-06-03","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":0.76,"value":9120.0,"ownership":{"direct":true},"balance_after":105624,"source":{"system":"sec-edgar","filing":"0001437749-24-019370","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924019370/rdgdoc.xml","form_type":"4"}},{"id":1496815,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-05-31T20:56:08.000Z","date":"2024-05-31","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":0.6443,"value":7731.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.61 to $0.6502, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence."}],"balance_after":93624,"source":{"system":"sec-edgar","filing":"0001437749-24-018931","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924018931/rdgdoc.xml","form_type":"4"}},{"id":1496814,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-05-31T20:56:08.000Z","date":"2024-05-30","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":0.6397,"value":7676.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.629 to $0.64, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence."}],"balance_after":81624,"source":{"system":"sec-edgar","filing":"0001437749-24-018931","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924018931/rdgdoc.xml","form_type":"4"}},{"id":1496813,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-05-31T20:56:08.000Z","date":"2024-05-29","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":0.6369,"value":7642.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.629 to $0.637, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence."}],"balance_after":69624,"source":{"system":"sec-edgar","filing":"0001437749-24-018931","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924018931/rdgdoc.xml","form_type":"4"}},{"id":1502210,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2024-05-24T20:59:02.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 6/48ths on November 21, 2024 and 1/48th per month thereafter."}],"balance_after":25000,"derivative":{"exercise_price":0.6146,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001437749-24-018353","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924018353/rdgdoc.xml","form_type":"4"}},{"id":1553896,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2024-04-03T00:35:07.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":false,"shares":8952,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":82223,"derivative":{"underlying":"Common Stock","underlying_shares":8952},"source":{"system":"sec-edgar","filing":"0001437749-24-010723","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924010723/rdgdoc.xml","form_type":"4"}},{"id":1553895,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-04-03T00:35:07.000Z","date":"2024-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":3098,"price":0.681,"value":2109.738,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":57624,"source":{"system":"sec-edgar","filing":"0001437749-24-010723","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924010723/rdgdoc.xml","form_type":"4"}},{"id":1553894,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-04-03T00:35:07.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":true,"shares":8952,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":60722,"source":{"system":"sec-edgar","filing":"0001437749-24-010723","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924010723/rdgdoc.xml","form_type":"4"}},{"id":1693153,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-04T00:39:07.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":false,"shares":8952,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":91175,"derivative":{"underlying":"Common Stock","underlying_shares":8952},"source":{"system":"sec-edgar","filing":"0001437749-24-000486","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924000486/rdgdoc.xml","form_type":"4"}},{"id":1693152,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-01-04T00:39:07.000Z","date":"2023-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":3098,"price":0.3402,"value":1053.9396,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":51770,"source":{"system":"sec-edgar","filing":"0001437749-24-000486","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924000486/rdgdoc.xml","form_type":"4"}},{"id":1693151,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-01-04T00:39:07.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":true,"shares":8952,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":54868,"source":{"system":"sec-edgar","filing":"0001437749-24-000486","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774924000486/rdgdoc.xml","form_type":"4"}},{"id":1767872,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2023-10-03T23:30:33.000Z","date":"2023-09-30","kind":"exercise","planned":false,"acquired":false,"shares":8953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":100127,"derivative":{"underlying":"Common Stock","underlying_shares":8953},"source":{"system":"sec-edgar","filing":"0001437749-23-027581","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774923027581/rdgdoc.xml","form_type":"4"}},{"id":1767871,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-10-03T23:30:33.000Z","date":"2023-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":2624,"price":0.6199,"value":1626.6176,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":45916,"source":{"system":"sec-edgar","filing":"0001437749-23-027581","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774923027581/rdgdoc.xml","form_type":"4"}},{"id":1767870,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-10-03T23:30:33.000Z","date":"2023-09-30","kind":"exercise","planned":false,"acquired":true,"shares":8953,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":48540,"source":{"system":"sec-edgar","filing":"0001437749-23-027581","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774923027581/rdgdoc.xml","form_type":"4"}},{"id":1839851,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2023-07-03T22:51:02.000Z","date":"2023-06-30","kind":"exercise","planned":false,"acquired":false,"shares":13841,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,889 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,889 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":109080,"derivative":{"underlying":"Common Stock","underlying_shares":13841},"source":{"system":"sec-edgar","filing":"0001437749-23-019263","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774923019263/rdgdoc.xml","form_type":"4"}},{"id":1839850,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-07-03T22:51:02.000Z","date":"2023-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":4057,"price":0.855,"value":3468.735,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":39587,"source":{"system":"sec-edgar","filing":"0001437749-23-019263","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774923019263/rdgdoc.xml","form_type":"4"}},{"id":1839849,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-07-03T22:51:02.000Z","date":"2023-06-30","kind":"exercise","planned":false,"acquired":true,"shares":13841,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":43644,"source":{"system":"sec-edgar","filing":"0001437749-23-019263","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774923019263/rdgdoc.xml","form_type":"4"}},{"id":1928892,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2023-04-04T21:15:09.000Z","date":"2023-03-31","kind":"exercise","planned":false,"acquired":false,"shares":4063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":44687,"derivative":{"underlying":"Common Stock","underlying_shares":4063},"source":{"system":"sec-edgar","filing":"0001437749-23-009330","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774923009330/rdgdoc.xml","form_type":"4"}},{"id":1928891,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-04-04T21:15:09.000Z","date":"2023-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":1154,"price":1.39,"value":1604.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units."}],"balance_after":29803,"source":{"system":"sec-edgar","filing":"0001437749-23-009330","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774923009330/rdgdoc.xml","form_type":"4"}},{"id":1928890,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-04-04T21:15:09.000Z","date":"2023-03-31","kind":"exercise","planned":false,"acquired":true,"shares":4063,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":30957,"source":{"system":"sec-edgar","filing":"0001437749-23-009330","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774923009330/rdgdoc.xml","form_type":"4"}},{"id":2033368,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-03T23:44:42.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":78234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2023 and 3/48ths per quarter thereafter (September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025, March 31, 2026, June 30, 2026, September 30, 2026, December 31, 2026)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2023 and 3/48ths per quarter thereafter (September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025, March 31, 2026, June 30, 2026, September 30, 2026, December 31, 2026)"}],"balance_after":126984,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":78234},"source":{"system":"sec-edgar","filing":"0001437749-23-002515","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774923002515/rdgdoc.xml","form_type":"4"}},{"id":2033367,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2023-02-03T23:44:42.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":102688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 6/48ths on June 30, 2023 and 1/48th per month thereafter."}],"balance_after":102688,"derivative":{"exercise_price":3.16,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":102688},"source":{"system":"sec-edgar","filing":"0001437749-23-002515","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774923002515/rdgdoc.xml","form_type":"4"}},{"id":2072868,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2023-01-03T21:07:10.000Z","date":"2022-12-31","kind":"exercise","acquired":false,"shares":4062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":48750,"derivative":{"underlying":"Common Stock","underlying_shares":4062},"source":{"system":"sec-edgar","filing":"0001437749-23-000169","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774923000169/rdgdoc.xml","form_type":"4"}},{"id":2072867,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-01-03T21:07:10.000Z","date":"2022-12-31","kind":"tax_withholding","acquired":false,"shares":1406,"price":2.37,"value":3332.22,"ownership":{"direct":true},"balance_after":26894,"source":{"system":"sec-edgar","filing":"0001437749-23-000169","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774923000169/rdgdoc.xml","form_type":"4"}},{"id":2072866,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-01-03T21:07:10.000Z","date":"2022-12-31","kind":"exercise","acquired":true,"shares":4062,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":28300,"source":{"system":"sec-edgar","filing":"0001437749-23-000169","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000143774923000169/rdgdoc.xml","form_type":"4"}},{"id":2114738,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-11-16T21:58:33.000Z","date":"2022-11-15","kind":"purchase","acquired":true,"shares":10000,"price":3.15,"value":31500.0,"ownership":{"direct":true},"balance_after":24238,"source":{"system":"sec-edgar","filing":"0001863624-22-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000186362422000001/primary_doc.xml","form_type":"4"}},{"id":2114737,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-11-16T21:58:33.000Z","date":"2022-11-14","kind":"purchase","acquired":true,"shares":6053,"price":3,"value":18159.0,"ownership":{"direct":true},"balance_after":14238,"source":{"system":"sec-edgar","filing":"0001863624-22-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000186362422000001/primary_doc.xml","form_type":"4"}},{"id":2147591,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-03T23:42:36.000Z","date":"2022-09-30","kind":"exercise","acquired":false,"shares":4063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 2, 2022,  the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 2, 2022,  the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":52812,"derivative":{"underlying":"Common Stock","underlying_shares":4063},"source":{"system":"sec-edgar","filing":"0001654954-22-013278","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000165495422013278/section16.xml","form_type":"4"}},{"id":2147590,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-10-03T23:42:36.000Z","date":"2022-09-30","kind":"tax_withholding","acquired":false,"shares":1191,"price":1.52,"value":1810.32,"ownership":{"direct":true},"balance_after":8185,"source":{"system":"sec-edgar","filing":"0001654954-22-013278","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000165495422013278/section16.xml","form_type":"4"}},{"id":2147589,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-10-03T23:42:36.000Z","date":"2022-09-30","kind":"exercise","acquired":true,"shares":4063,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":9376,"source":{"system":"sec-edgar","filing":"0001654954-22-013278","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000165495422013278/section16.xml","form_type":"4"}},{"id":2217482,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2022-07-01T20:17:54.000Z","date":"2022-06-30","kind":"exercise","acquired":false,"shares":8125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 2, 2022,  the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 2, 2022,  the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement."}],"balance_after":56875,"derivative":{"underlying":"Common Stock","underlying_shares":8125},"source":{"system":"sec-edgar","filing":"0001654954-22-009149","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000165495422009149/section16.xml","form_type":"4"}},{"id":2217481,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-07-01T20:17:54.000Z","date":"2022-06-30","kind":"tax_withholding","acquired":false,"shares":2812,"price":2.299,"value":6464.788,"ownership":{"direct":true},"balance_after":5313,"source":{"system":"sec-edgar","filing":"0001654954-22-009149","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000165495422009149/section16.xml","form_type":"4"}},{"id":2217480,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-07-01T20:17:54.000Z","date":"2022-06-30","kind":"exercise","acquired":true,"shares":8125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired on vesting and settlement of restricted stock units."}],"balance_after":8125,"source":{"system":"sec-edgar","filing":"0001654954-22-009149","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000165495422009149/section16.xml","form_type":"4"}},{"id":2411843,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-05T00:29:56.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025)"}],"balance_after":65000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001654954-22-001167","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000165495422001167/section16.xml","form_type":"4"}},{"id":2411842,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2022-02-05T00:29:56.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter."}],"balance_after":85000,"derivative":{"exercise_price":2.8,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001654954-22-001167","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000165495422001167/section16.xml","form_type":"4"}},{"id":2645318,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2021-07-02T21:07:03.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 6/48ths on November 30, 2021 and 1/48th monthly on the last day of each month thereafter."}],"balance_after":30000,"derivative":{"exercise_price":5.89,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001654954-21-007591","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000165495421007591/section16.xml","form_type":"4"}},{"id":2687014,"issuer":{"id":5152,"kind":"organization","name":"Monopar Therapeutics","symbol":"MNPR"},"owners":[{"id":32951,"kind":"person","name":"Cittadine Andrew","position":1,"cik":"0001863624","reported_name":"Cittadine Andrew","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2021-06-02T20:11:49.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 6/48ths on November 30, 2021 and 1/48th monthly on the last day of each month thereafter."}],"balance_after":70000,"derivative":{"exercise_price":5.76,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001654954-21-006531","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863624/000165495421006531/section16.xml","form_type":"4"}}]}